Theratechnologies Inc T.TH

New Press Release - Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patientsPreliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesionMONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc....read article.

[palinc2000]

Very limited signs of efficacy...The real question is  Will they be able to find a partner?

[palinc2000]

The best outcome would be  Out Licensing with an upfront payment  between of at least 20 millions$ and milestone payments plus royalties Achievable ????  

[Mannequin]

Forget the total here. They were looking at dosing.  And 50% of patients with evidence in ARM B... "there was encouraging evidence of activity observed in three of the six patients enrolled in the Arm B PP set, including one patient with a complete resolution of a liver lesion. Those three Arm B patients also experienced significant reductions in the CA-125 ovarian tumor marker as well

[Trogarzon]

This is good....

[Joemare]

Very encouraging actually! Heavily treated patients. No safety issues.  I'm a little suprised at the data. Moving upwards from here. We need a bigger buzz around this technology.  They need a few of those twitter folks jump on the bandwagon.